Evidence map›Paper›PMID 32307659›Full record

ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2020

Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals.

Lawrence Drudge-Coates, Tim Van den Wyngaert, Morten Schiødt, H A M van Muilekom, Gaston Demonty, Sven Otto

Open access · hybridAbstract readCase ReportsReview
In one paragraph

Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Introducing equivalent and threshold doses in the assessment of medication-related osteonecrosis of the jaw risk: insights from a descriptive study in Iran.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Bridging the gap - Establishing a dental-oncology service in a cancer centre.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  12. How we manage medication-related osteonecrosis of the jaw.European journal of medical research · 2024
    Review
  13. Article
  14. Article
  15. A cross-sectional study on Chinese oncology nurses' knowledge of bone health among cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 6 countries.

Lawrence Drudge-CoatesDepartment of Urology, King's College Hospital NHS Foundation Trust, Denmark Hill, London, SE5 9RS, UK. ldrudge-coates@nhs.net.
Tim Van den WyngaertDepartment of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium.
Morten SchiødtDepartment of Oral and Maxillofacial Surgery, Rigshospitalet, Copenhagen, Denmark.
H A M van MuilekomDepartment of Urology, Antoni van Leeuwenhoek Hospital-Netherlands Cancer Institute, Amsterdam, Netherlands.
Gaston DemontyMedical Development, Amgen (Europe) GmbH, Rotkreuz, Switzerland.
Sven OttoDepartment of Oral and Maxillofacial Surgery, Ludwig-Maximilians-University of Munich, Munich, Germany.
Aarhus University Hospital · DKAmgen (Switzerland) · CHAntwerp University Hospital · BEKing's College Hospital NHS Foundation Trust · GBLudwig-Maximilians-Universität München · DENetherlands Cancer Institute-Antoni van Leeuwenhoek Hospital · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMedication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but potentially serious, adverse event that can occur after exposure to bone-modifying agents (BMAs; e.g., bisphosphonates, denosumab, and antiangiogenic therapies). BMAs are typically used at higher doses to prevent skeletal-related events in cancer patients and at lower doses for osteoporosis/bone loss. MRONJ can cause significant pain, reduce quality of life, and can be difficult to treat, requiring a multiprofessional approach to care.

methodsWe reviewed the literature and guidelines to summarize a practical guide on MRONJ for nurses and other allied healthcare professionals.

resultsWhile there is a risk of MRONJ with BMAs, this should be considered in relation to the benefits of treatment. Nurses and other allied healthcare professionals can play a key role alongside physicians and dentists in assessing MRONJ risk, identifying MRONJ, counseling the patient on the benefit-risk of BMA treatment, preventing MRONJ, and managing the care pathway of these patients. Assessing patients for MRONJ risk factors before starting BMA treatment can guide preventative measures to reduce the risk of MRONJ. Nurses can play a pivotal role in facilitating multiprofessional management of MRONJ by communicating with patients to ensure compliance with preventative measures, and with patients' physicians and dentists to ensure early detection and referral for prompt treatment of MRONJ.

conclusionsThis review summarizes current evidence on MRONJ and provides practical guidance for nurses, from before BMA treatment is started through to approaches that can be taken to prevent and manage MRONJ in patients receiving BMAs.

Indexed as

Allied Health PersonnelBisphosphonate-Associated Osteonecrosis of the JawFemaleHumansMiddle AgedNursesRisk FactorsAwarenessClinical managementCounselingJaw necrosisMRONJ

Identifiers

PMID32307659
PMCPMC7378104
OpenAlexW3016325444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.